First-ever public health agenda for psoriasis and psoriatic arthritis gives federal recognition to millions with psoriatic diseases
PORTLAND, Ore. (February 12, 2013)—The Centers for Disease Control and Prevention (CDC) led collaborative efforts among clinical, biomedical and public health experts to develop the first-ever public health agenda for psoriasis and psoriatic arthritis, giving federal recognition to millions of Americans living with these diseases.
A short article on the agenda was released online today in the American Journal of Preventative Medicine, highlighting the gaps in psoriatic disease research to guide future public health efforts into these diseases.
"Psoriasis and psoriatic arthritis have many genetic and environmental causes that vary among individuals," said Andrew D. Robertson, chief scientific and medical officer for the National Psoriasis Foundation. "A public health approach to psoriatic diseases will allow scientists to better identify possible environmental contributions, which could potentially help us stop these diseases before they start."
In 2009, after a multi-year advocacy campaign by National Psoriasis Foundation advocates and leaders, Congress allocated $1.5 million to the CDC to commence the first-ever government data collection effort on psoriasis and psoriatic arthritis. Through extensive collaboration, the coalition created a list of priorities, needs and unanswered questions in psoriatic disease research.
"Public health efforts exist for other chronic diseases like heart disease and diabetes, yet psoriasis and psoriatic arthritis have not had similar attention, despite their prevalence and profound burden on health care costs, quality of life and employment," said Randy Beranek, National Psoriasis Foundation president and CEO.
The public health agenda focuses on four priorities:
- Determining if current ways of diagnosing psoriasis and psoriatic arthritis can be applied to wider population-based research.
- Examining the prevalence, disparities and comorbidities, such as heart disease, of psoriasis and psoriatic arthritis.
- Looking at health-care use, costs and work burden associated with psoriatic diseases.
- Studying the impact of psoriasis and psoriatic arthritis disease severity on quality of life and other outcomes.
A chronic, genetic disease of the immune system, psoriasis is the most prevalent autoimmune disease in the country, affecting as many as 7.5 million Americans. Psoriasis puts people at increased risk for other health concerns such as heart disease, diabetes and obesity. Up to 30 percent of people with psoriasis develop psoriatic arthritis, an inflammatory arthritis that affects the joints and tendons. If left untreated, it can cause irreversible joint damage.
The agenda clearly states the need for research into basic questions, such as the age at which psoriasis and psoriatic arthritis appear, how the diseases start and develop over time, and possible differences in how they affect certain groups, such as younger versus older people.
"To successfully answer these questions, and address other research needs, the engagement of the larger dermatology and public health communities is needed," Robertson said. "The Psoriasis Foundation looks forward to creating opportunities that facilitate involvement among interested parties to move this public health agenda forward."
About the National Psoriasis Foundation
Celebrating 50 years of patient support, advocacy, research funding, and education, the National Psoriasis Foundation (NPF) is the world’s leading nonprofit fighting for individuals with psoriasis and psoriatic arthritis. NPF is on a continued mission to drive efforts to cure psoriatic disease and dramatically improve the lives of more than 8 million Americans affected by this chronic immune mediated disease. As part of that effort, in 2016 the NPF created a Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. In addition, the NPF has funded more than $15 million in research grants and fellowships to date. Learn more at www.psoriasis.org.